Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 11/20 | 0.49 |
| ▸ | CNR1 | P21554 | 5/20 | 0.49 |
| ▸ | BCHE | P06276 | 7/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652410 | 0.87 | HDAC1 (0.52) | HDAC1HDAC8CNR2CNR1BCHE | |
| SCHEMBL2653126 | 0.86 | HDAC1 (0.61) | HDAC1HDAC8PLK1EHMT2EHMT1 | |
| SCHEMBL2665472 | 0.84 | HDAC1 (0.51) | HDAC1HDAC8CNR2CNR1BCHE | |
| SCHEMBL2653215 | 0.83 | PTGER4 (0.46) | HDAC1HDAC8JAK2JAK1TYK2 | |
| SCHEMBL2650851 | 0.82 | HDAC1 (0.50) | HDAC1HDAC8JAK2JAK1TYK2 | |
| SCHEMBL2652187 | 0.80 | HDAC1 (0.54) | HDAC1HDAC8PLK1EHMT2 | |
| SCHEMBL2651153 | 0.79 | HDAC1 (0.52) | HDAC1HDAC8PLK1EHMT2EHMT1 | |
| SCHEMBL9070767 | 0.78 | HDAC1 (0.50) | HDAC1HDAC8PLK1EHMT2EHMT1 | |
| SCHEMBL2651954 | 0.78 | EHMT2 (0.47) | HDAC1HDAC8PLK1EHMT2EHMT1 | |
| SCHEMBL9070781 | 0.77 | HDAC1 (0.54) | HDAC1HDAC8JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | HDAC1 3760/4885HDAC8 2464/4885CNR2 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.